Селективные агонисты <х2-адренорецепторов в лечении глаукомы
Аннотация
В обзоре рассматриваются ключевые фармакотерапевтиче-ские характеристики селективных агонистов адренорецепто-ров, включая аффинность к адренорецепторам, гипотензивный механизм и возможные способы нейропротекторного действия. Также приведено сравнение профилей эффективности и безопасности бримонидина и других антиглаукомных препаратов.
Об авторе
Алевтина Евгеньевна Дугина
Центр микрохирургии глаза Дорожной клинической больницы им. Н.А. Семашко
Россия
Россия
Список литературы
1. Rahman M.Q., Ramaesh K., Montgomery D.M. Brimonidine for glaucoma. Expert Opin Drug Saf 2010; 9:483-491.
2. Jimmy D.B., Siret D.J. Clinical ocular pharmacology. Elsevier Health Sciences 2008; 793 p.
3. Sponsel W.E., Paris G., Trigo Y., Pena M., Weber A., Sanford K., McKinnon S. Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy. Am J Ophthalmol 2002; 133:11-18.
4. Abud T.B., Scuoteguazza F.M., Oliveira E.S., Abud J.F., Prata Junior J.A. Hypotensive effect of three different formulations of brimonidine tartrate in normal eyes. Arq Bras Oftalmol 2013; 76:69-71.
5. Kim C.Y., Hong S., Seong G.J. Brimonidine 0.2% versus brimonidine Purite 0.15% in Asian ocular hypertension. J Ocul Pharmacol Ther 2007; 23:481-486.
6. Zhang N., Kannan R., Okamoto C.T., Ryan S.J., Lee V.H., Hinton D.R. Characterization of brimonidine transport in retinal pigment epithelium. Invest Ophthalmol Vis Sci 2006; 47:287-294.
7. Acheampong A.A., Shackleton M., John B., Burke J., Wheeler L., Tang-Liu D. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. Drug Metab Dispos 2002; 30:421-429.
8. Acheampong A.A, Shackleton M., Tang-Liu D.D. Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits. Drug Metab Dispos 1995; 23:708-712.
9. Bezprozvanny I. Calcium signaling and neurodegenerative diseases. Trends Mol Med 2009; 15:89-100.
10. Das A., Sribnick E.A., Wingrave J.M., Del Re A.M., Woodward J.J., Appel S.H., Banik N.L., Ray S.K. Calpain activation in apoptosis of ventral spinal cord 4.1 (VSC4.1) motoneurons exposed to glutamate: calpain inhibition provides functional neuroprotection. J Neurosci Res 2005; 81:551-562.
11. Sharma A.K., Rohrer B. Calcium-induced calpain mediates apoptosis via caspase-3 in a mouse photoreceptor cell line. J Biol Chem 2004; 279:35564-35572.
12. Brennan A.M., Suh S.W., Won S.J., Narasimhan P., Kauppin-en T.M., Lee H., Edling Y., Chan P.H., Swanson R.A. NADPH oxidase is the primary source of superoxide induced by NMDA receptor activation. Nat Neurosci 2009; 12:857-863.
13. Sattler R., Xiong Z., Lu W.Y., Hafner M., MacDonald J.F., Tymianski M. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science 1999; 284:1845-1848.
14. Lee D., Kim K., Noh Y.H., Chai S., Lindsey J.D., Ellisman M.H., Weinreb R.N., Ju W.-K. Brimonidine blocks glutamate excito-toxicity-induced oxidative stress and preserves mitochondri-al transcription factor a in ischemic retinal injury. PLoS One 2012; 7.
15. Starke K. Presynaptic autoreceptors in the third decade: focus on alpha2-adrenoceptors. JNeurochem 2001; 78:685-693.
16. Boehm S. Presynaptic alpha2-adrenoceptors control excitatory, but not inhibitory, transmission at rat hippocampal synapses. J Physiol 1999; 519 Pt 2:439-449.
17. Biinemann M., Biicheler M.M., Philipp M., Lohse M.J., Hein L. Activation and deactivation kinetics of alpha 2A- and alpha 2C-adrenergic receptor-activated G protein-activated inwardly rectifying K+ channel currents. J Biol Chem 2001; 276:4751247517.
18. Delaney A.J., Crane J.W., Sah P. Noradrenaline modulates transmission at a central synapse by a presynaptic mechanism. Neuron 2007; 56:880-892.
19. Dong C.J., Guo Y., Agey P., Wheeler L., Hare W.A. Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest Ophthalmol Vis Sci 2008; 49: 4515-4522.
20. Hare W.A., WoldeMussie E., Lai R.K., Ton H., Ruiz G., Chun T., Wheeler L. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures. Invest Ophthalmol Vis Sci 2004; 45:2625-2639.
21. Ju W.K., Kim K.Y., Angert M., Duong-Polk K.X., Lindsey J.D., Ellisman M.H., Weinreb R.N. Memantine blocks mitochondrial OPA1 and cytochrome c release and subsequent apoptotic cell death in glaucomatous retina. Invest Ophthalmol Vis Sci 2009; 50:707-716.
22. Sattler R., Tymianski M. Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death. Mol Neurobiol 2001; 24:107-129.
23. WoldeMussie E., Yoles E., Schwartz M., Ruiz G., Wheeler L.A. Neuroprotective effect of memantine in different retinal injury models in rats. J Glaucoma 2002; 11:474-480.
24. Lambert W.S., Ruiz L., Crish S.D., Wheeler L.A., Calkins D.J. Brimonidine prevents axonal and somatic degeneration of retinal ganglion cell neurons. Mol Neurodegener 2011; 6:4.
25. Lopez-Herrera M.P.L., Mayor-Torroglosa S., de Imperial J.M., Villegas-Perez M.P., Vidal-Sanz M. Transient ischemia of the retina results in altered retrograde axoplasmic transport: neuroprotection with brimonidine. Exp Neurol 2002; 178:243-258.
26. Donello J.E., Padillo E.U., Webster M.L., Wheeler L.A., Gil D.W. Alpha(2)-Adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J Pharmacol Exp Ther 2001; 296:216-223.
27. Lai R.K., Chun T., Hasson D., Lee S., Mehrbod F., Wheeler L. Alpha-2 adrenoceptor agonist protects retinal function after acute retinal ischemic injury in the rat. Vis Neurosci 2002; 19:175-185.
28. Hernandez M., Urcola J.H., Vecino E. Retinal ganglion cell neuroprotection in a rat model of glaucoma following brimo-nidine, latanoprost or combined treatments. Exp Eye Res 2008; 86:798-806.
29. WoldeMussie E., Ruiz G., Wijono M., Wheeler L.A. Neuropro-tection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci 2001; 42:2849-2855.
30. DuBiner H.B., Mroz M., Shapiro A.M., Dirks M.S. A comparison of the efficacy and tolerability of brimonidine and latano-prost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, doublemasked, parallel-group trial. Clin Ther 2001; 23:1969-1983.
31. Chen M.J., Chou J.C., Hsu W.M., Liu J.H. The efficacy and safety of brimonidine 0.2% compared with timolol 0.5% in glaucoma: a randomized clinical trial on Taiwanese patients. J Chin Med Assoc 2003; 66:276-281.
32. Javitt J.C., Schiffman R.M. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular t hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I. J Glaucoma 2000; 9:224-234.
33. Whitson J.T., Henry C., Hughes B., Lee D.A., Terry S., Fechtner R.D. Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Glaucoma 2004; 13:168-173.
34. Melamed S., David R. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timo-lol: year-three results. Brimonidine Study Group II. Clin Ther 2000; 22:103-111.
35. Einarson T.R., Kulin N.A., Tingey D., Iskedjian M. Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma. Clin Ther 2000; 22:1502-1515.
36. Cantor L.B., Hoop J., Katz L.J., Flartey K. Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25% suspension in patients with elevated intraocular pressure. Clin Ther 2001; 23:1032-1039.
37. Javitt J., Goldberg I. Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II. J Glaucoma 2000; 9:398-408.
38. Schuman J.S. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol 1996; 41 Suppl 1:27-37.
39. Camras C.B., Sheu W.P., United States Latanoprost-Brimoni-dine Study Group. Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States. J Glaucoma 2005; 14:161-167.
40. Kampik A., Arias-Puente A., O'Brart D.P., Vuori M.L., European Latanoprost Study Group. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study. J Glaucoma 2002; 11:90-96.
41. Stewart W.C., Day D.G., Stewart J.A., Holmes K.T., Leech J.N., Rowan C.T., Schwartz G.F. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2000; 16:557-564.
42. Thomas R., Parikh R., Muliyil J., George R., Paul P., Abraham L.M. Comparison between latanoprost and brimonidine efficacy and safety in Indian eyes. Indian J Ophthalmol 2003; 51:123-128.
43. Craven E.R., Walters T.R., Williams R., Chou C., Cheetham J.K., Schiffman R. Combigan Study Group. Brimonidine and timo-lol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2005; 21:337-348.
44. Centofanti M., Manni G., Gregori D., Cocco F., Lorenzano D., Bucci M.G. Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma. Graefes Arch Clin Exp Ophthalmol 2000; 238:302-305.
45. Simmons S.T. Alphagan/Trusopt Study Group. Efficacy of bri-monidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension. Clin Ther 2001; 23:604-619.
46. Bozic M., Hentova-Sencic P., Kontic D., Markovic V., Marjano-vi6 I. Prevention of intraocular pressure elevation after argon laser trabeculoplasty in primary open angle glaucoma. Srp Arh Celok Lek 2011; 139:12-17.
47. Singhal D., Desai R., Desai S., Shastri M., Saxena D. Use of topical brimonidine to prevent intraocular pressure elevations following Nd: YAG-laser posterior capsulotomy. J Pharmacol Pharmacother 2011; 2:104-106.
48. Coppens G., Stalmans I., Zeyen T., Casteels I. The safety and efficacy of glaucoma medication in the pediatric population. JPediatr Ophthalmol Strabismus 2009; 46:12-18.
49. Lai Becker M., Huntington N., Woolf A.D. Brimonidine tartrate poisoning in children: frequency, trends, and use of naloxone as an antidote. Pediatrics 2009; 123:305-311.
50. Moore W., Nischal K.K. Pharmacologic management of glaucoma in childhood. Paediatr Drugs 2007; 9:71-79.
51. Salim S. Glaucoma in pregnancy. Curr Opin Ophthalmol 2014; 25:93-97.
52. Razeghinejad M.R., Tania T.T.Y., Fudemberg S.J., Katz L.J. Pregnancy and glaucoma. Surv Ophthalmol 2011; 56:324-335.
Рецензия
Для цитирования:
Дугина А.Е. Селективные агонисты <х2-адренорецепторов в лечении глаукомы. Национальный журнал Глаукома. 2014;13(3):95-100.
For citation:
Dugina A.E. Selective of a2-adrenoceptor agonists in glaucoma treatment. National Journal glaucoma. 2014;13(3):95-100. (In Russ.)
Просмотров: 446
Послать статью по эл. почте 